Overcoming implementation challenges of personalized cancer therapy

Funda Meric-Bernstam, Gordon Mills

Research output: Contribution to journalReview article

76 Citations (Scopus)

Abstract

Personalized cancer therapy is based on the precept that detailed molecular characterization of the patient's tumour and its microenvironment will enable tailored therapies to improve outcomes and decrease toxicity. The goal of personalized therapy is to target aberrations that drive tumour growth and survival, by administering the right drug combination for the right person. This is becoming increasingly achievable with advances in high-throughput technologies to characterize tumours and the expanding repertoire of molecularly targeted therapies. However, there are numerous challenges that need to be surpassed before delivering on the promise of personalized cancer therapy. These include tumour heterogeneity and molecular evolution, costs and potential morbidity of biopsies, lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles. Critically, the 'hype' surrounding personalized cancer therapy must be tempered with realistic expectations, which, today, encompass increased survival times for only a portion of patients.

Original languageEnglish (US)
Pages (from-to)542-548
Number of pages7
JournalNature Reviews Clinical Oncology
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Tumor Microenvironment
Survival
Molecular Evolution
Drug Combinations
Technology
Morbidity
Biopsy
Costs and Cost Analysis
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Overcoming implementation challenges of personalized cancer therapy. / Meric-Bernstam, Funda; Mills, Gordon.

In: Nature Reviews Clinical Oncology, Vol. 9, No. 9, 01.09.2012, p. 542-548.

Research output: Contribution to journalReview article

@article{5099955a7d324947b0c0082f1b2889dd,
title = "Overcoming implementation challenges of personalized cancer therapy",
abstract = "Personalized cancer therapy is based on the precept that detailed molecular characterization of the patient's tumour and its microenvironment will enable tailored therapies to improve outcomes and decrease toxicity. The goal of personalized therapy is to target aberrations that drive tumour growth and survival, by administering the right drug combination for the right person. This is becoming increasingly achievable with advances in high-throughput technologies to characterize tumours and the expanding repertoire of molecularly targeted therapies. However, there are numerous challenges that need to be surpassed before delivering on the promise of personalized cancer therapy. These include tumour heterogeneity and molecular evolution, costs and potential morbidity of biopsies, lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles. Critically, the 'hype' surrounding personalized cancer therapy must be tempered with realistic expectations, which, today, encompass increased survival times for only a portion of patients.",
author = "Funda Meric-Bernstam and Gordon Mills",
year = "2012",
month = "9",
day = "1",
doi = "10.1038/nrclinonc.2012.127",
language = "English (US)",
volume = "9",
pages = "542--548",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Overcoming implementation challenges of personalized cancer therapy

AU - Meric-Bernstam, Funda

AU - Mills, Gordon

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Personalized cancer therapy is based on the precept that detailed molecular characterization of the patient's tumour and its microenvironment will enable tailored therapies to improve outcomes and decrease toxicity. The goal of personalized therapy is to target aberrations that drive tumour growth and survival, by administering the right drug combination for the right person. This is becoming increasingly achievable with advances in high-throughput technologies to characterize tumours and the expanding repertoire of molecularly targeted therapies. However, there are numerous challenges that need to be surpassed before delivering on the promise of personalized cancer therapy. These include tumour heterogeneity and molecular evolution, costs and potential morbidity of biopsies, lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles. Critically, the 'hype' surrounding personalized cancer therapy must be tempered with realistic expectations, which, today, encompass increased survival times for only a portion of patients.

AB - Personalized cancer therapy is based on the precept that detailed molecular characterization of the patient's tumour and its microenvironment will enable tailored therapies to improve outcomes and decrease toxicity. The goal of personalized therapy is to target aberrations that drive tumour growth and survival, by administering the right drug combination for the right person. This is becoming increasingly achievable with advances in high-throughput technologies to characterize tumours and the expanding repertoire of molecularly targeted therapies. However, there are numerous challenges that need to be surpassed before delivering on the promise of personalized cancer therapy. These include tumour heterogeneity and molecular evolution, costs and potential morbidity of biopsies, lack of effective drugs against most genomic aberrations, technical limitations of molecular tests, and reimbursement and regulatory hurdles. Critically, the 'hype' surrounding personalized cancer therapy must be tempered with realistic expectations, which, today, encompass increased survival times for only a portion of patients.

UR - http://www.scopus.com/inward/record.url?scp=84865677954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865677954&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2012.127

DO - 10.1038/nrclinonc.2012.127

M3 - Review article

VL - 9

SP - 542

EP - 548

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 9

ER -